@article{d878397e58f949f1b071520a26ac98f0,
title = "Vaccines and Allergic reactions: The past, the current COVID-19 pandemic, and future perspectives",
abstract = "Vaccines are essential public health tools with a favorable safety profile and prophylactic effectiveness that have historically played significant roles in reducing infectious disease burden in populations, when the majority of individuals are vaccinated. The COVID-19 vaccines are expected to have similar positive impacts on health across the globe. While serious allergic reactions to vaccines are rare, their underlying mechanisms and implications for clinical management should be considered to provide individuals with the safest care possible. In this review, we provide an overview of different types of allergic adverse reactions that can potentially occur after vaccination and individual vaccine components capable of causing the allergic adverse reactions. We present the incidence of allergic adverse reactions during clinical studies and through post-authorization and post-marketing surveillance and provide plausible causes of these reactions based on potential allergenic components present in several common vaccines. Additionally, we review implications for individual diagnosis and management and vaccine manufacturing overall. Finally, we suggest areas for future research.",
keywords = "COVID-19, SARS-CoV-2, allergy, anaphylaxis, vaccine",
author = "Vanitha Sampath and Grace Rabinowitz and Mihir Shah and Surabhi Jain and Zuzana Diamant and Milos Jesenak and Ronald Rabin and Stefan Vieths and Ioana Agache and Akdis, \{M. beccel\} and Domingo Barber and Heimo Breiteneder and Sharon Chinthrajah and Tomas Chivato and William Collins and Thomas Eiwegger and Katharine Fast and Wytske Fokkens and O'Hehir, \{Robyn E.\} and Markus Ollert and Liam O'Mahony and Oscar Palomares and Oliver Pfaar and Carmen Riggioni and Shamji, \{Mohamed H.\} and Milena Sokolowska and \{Jose Torres\}, Maria and Claudia Traidl-Hoffmann and \{van Zelm\}, Menno and Wang, \{De Yun\} and Luo Zhang and Akdis, \{Cezmi A.\} and Nadeau, \{Kari C.\}",
note = "Funding Information: We would like to thank the Parker foundation, the Sunshine foundation, the Crown Foundation, and the NIAID SARS Vaccine study for funding the study. Funding Information: Dr. Diamant reports personal fees from ALK, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HAL Allergy, Merck Sharp \& Dohme, and Sanofi‐Genzyme‐Regeneron and acted as Research Directorat QPS‐NL, an institution which received research support from several bio‐pharmaceutical companies, esp within respiratory: HAL Allergy, Foresee Pharmaceuticals, Patara Pharma (now Respivant), Novartis; Dr. Jesenak received honoraria, consultancy and speaker fees from Sanofi‐Pasteur, Pfizer, GlaxoSmithKline, Merck Sharp\&Dohme, Takeda, ALK, Stallergenes‐Greer, Angelini, Novartis, Mundipharma and Berlin‐Chemie and acted as principal investigator in trials sponsored by BioCryst, Pharming, Octapharma, and Baxalta; Dr. Vieths reports personal fees from Swiss Society for Allergy and Immunology, SchattauerAllergologieHandbuch, Elsevier Nahrungsmittelallergien und Intoleranzen, and Karger Food Allergy: Molecular Basis and Clinical Practice and also reports non‐financial support from German Research Foundation, European Directorate for the Quality of Medicines and Health Care, European Academy of Allergy and Clinical Immunology, German Chemical Society (GDCh), AKM Allergiekongress, International Union of Immunological Societies, and from Spanish Society for Allergy and Clinical Immunology (SEAIC); Dr. Agache is an Associate Editor at Allergy and PAI; Dr. Chinthrajah reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, and FARE and is an advisory board member of Alladapt Therapeutics, Genentech, Novartis, and Sanofi; Dr. Eiwegger acts as local PI for company‐sponsored trials by DBV and sub‐investigator for Regeneron, holds grants from Innovation fund Denmark, CIHR. He is Co‐Investigator or scientific lead in three investigator‐initiated oral immunotherapy trials supported by the Food Allergy and Anaphylaxis Program SickKids and serves as associate editor for Allergy. He/his laboratory received unconditional/kind contributions from Macro Array Diagnostics and ALK. He holds advisory board roles for ALK; Dr. Barber reports grants from ALK, ALLERO therapeutics, personal fees from ALK and Aimmune; Dr. Ollert reports personal fees from Hycor Biomedical and is Scientific co‐founder of TolerogenicsSarL; Dr. Palomares received research grants from Inmunotek S.L., Novartis and MINECO, received fees for giving scientific lectures or participation in Advisory Boards from Allergy Therapeutics, Amgen, AstraZeneca, Diater, GlaxoSmithKline, S.A, Inmunotek S.L, Novartis, Sanofi‐Genzyme and Stallergenes; Dr. Pfaar reports grants and personal fees from ALK‐Abell{\'o}, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, BencardAllergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A, Laboratorios LETI/LETI Pharma, Anergis S.A, and Glaxo Smith Kline, and grants from Biomay, Circassia, Pohl‐Boskamp, and Inmunotek S.L, and personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, and Paul‐Martini‐Stiftung (PMS); Dr. Sokolowska reports grants from Swiss National Science Foundation (SNF) and from GSK; Dr. Torres reports grants from European Comission, SEAIC, and ISCIII and personal fees from Diater laboratory, Leti laboratory, and consultancy from Aimmune Therapeutics; Dr. Traidl‐Hoffmann reports personal fees from Sanofi Genzyme, Lilly Pharma, Novartis, T{\"o}pfer, and grants and personal fees from Sebapharma; Dr. van Zelm reports grants from NHMRC and has a patent pending, “Methods for detecting immune response”; Dr. Akdis reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine K{\"u}hne‐Center for Allergy Research and Education, European Commission's Horizon's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, Scibase, advisory board from Sanofi/Regeneron, Glaxo Smith‐Kline, Scibase, and Novartis; Dr. Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), and National Institute of Environmental Health Sciences (NIEHS); Food Allergy Research \& Education (FARE), Director of World Allergy Organization (WAO) Center of Excellence at Stanford; Advisor at Cour Pharma; Co‐founder of Before Brands, Alladapt, Latitude, and IgGenix; National Scientific Committee member at Immune Tolerance Network (ITN) and National Institutes of Health (NIH) clinical research centers; DSMB member for NHLBI, US patents for basophil testing, multifood immunotherapy and prevention, monoclonal antibody from plasmablasts, and device for diagnostics. All other authors report no COI. Publisher Copyright: {\textcopyright} 2021 European Academy of Allergy and Clinical Immunology and John Wiley \& Sons Ltd.",
year = "2021",
month = jun,
doi = "10.1111/all.14840",
language = "English",
volume = "76",
pages = "1640--1660",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Blackwell",
number = "6",
}
SDG 3 Good Health and Well-being
SDG 9 Industry, Innovation, and Infrastructure